Is tumor survivin downregulated by the antisense oligonucleotide LY2181308 : a proof-of-concept , first-in-human dose study?
The tumor-specific, molecularly targeted effects demonstrated by this ASO in man underpin confirmatory studies evaluating its therapeutic efficacy in cancer.
Perioperative sepsis is a significant risk factor for postoperative DVT in the colorectal surgery population.